Table 1.
Socio-demographic and epidemiological characteristics of patients with confirmed COVID-19.
| Total | Symptomatic | Asymptomatic | p-Value | ||||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Diagnosed patients | 219,138 | 149,026 | 68.0% | 70,112 | 32.0% | ||
| Sex | |||||||
| Female | 117,220 | 53.5% | 81,034 | 54.4% | 36,186 | 51.6% | <0.001 |
| Male | 101,918 | 46.5% | 67,992 | 45.6% | 33,926 | 48.4% | <0.001 |
| Age groups | |||||||
| 0–14 | 28,225 | 12.9% | 12,723 | 8.5% | 15,502 | 22.1% | <0.001 |
| 15–44 | 87,108 | 39.8% | 63,977 | 42.9% | 23,131 | 33.0% | <0.001 |
| 45–64 | 63,103 | 28.8% | 47,437 | 31.8% | 15,666 | 22.3% | <0.001 |
| 65–80 | 24,831 | 11.3% | 16,796 | 11.3% | 8035 | 11.5% | 0.194 |
| >80 | 15,871 | 7.2% | 8093 | 5.4% | 7778 | 11.1% | <0.001 |
| Residents of nursing home | 7977 | 3.6% | 2186 | 1.5% | 5791 | 8.3% | <0.001 |
| Health care workers | 4539 | 2.1% | 3682 | 2.5% | 857 | 1.2% | <0.001 |
| Clinical evolution | |||||||
| Hospitalized | 8361 | 3.8% | 7021 | 4.7% | 1340 | 1.9% | <0.001 |
| Exitus | 4109 | 1.9% | 2313 | 1.6% | 1796 | 2.6% | <0.001 |
| Diagnostic tests | |||||||
| Ag-RDTs | 97,576 | 44.5% | 78,560 | 52.7% | 19,016 | 27.1% | |
| With any negative NAAT | 5796 | 7.4% | |||||
| NAAT | 106,484 | 48.6% | 58,667 | 39.4% | 47,817 | 68.2% | |
| With any negative Ag-RDTs | 14,522 | 24.8% | |||||
| Ag-RDTs + NAAT | 14,561 | 6.6% | 11,741 | 7.9% | 2820 | 4.0% | |
| ELISA IgM | 517 | 0.2% | 58 | 0.0% | 459 | 0.7% | |
| Total tests done | |||||||
| Ag-RDTs * | 181,276 | 32.60% | 139,462 | 38.90% | 41,814 | 21.10% | |
| Before SO * (Positives) | 31,063 (3212) | 22.3% (10.3%) | |||||
| After SO * (Positives) | 108,399 (88,743) | 77.7% (81.9%) | |||||
| NAAT * | 375,388 | 67.40% | 218,724 | 61.10% | 156,664 | 78.90% | |
| Before SO * (Positives) | 127,517 (21,568) | 58.3% (16.9%) | |||||
| After SO * (Positives) | 91,207 (67,722) | 41.7% (74.3%) | |||||
* Ag-RDTs: rapid antigenic tests; NAAT: nucleic acid amplification testing; SO: symptoms onset.